Clinical Trial Search

Primary: Feasibility of the Mindfulness Intervention in Women With Mild Cognitive Impairment — 18.3 score on a scale

Primary: Safety and Tolerability — 10; 8; 2; 0 Participants

Primary: Maximum Tolerated Dose of Entinostat Given in Combination With Pembrolizumab — 1; 2 Participants

Primary: Number of Participants Vaccinated at the End of the Campaign Period — 33357; 854 Participants — p=0.216

Primary: Systolic Blood Pressure — 93.21; 107.00; 95.8; 93.84 mmHg

Primary: Alcohol Use-Peak Drinks — 4.71; 4.79 number of drinks — p=>.05

Primary: Annualized Relapse Rate (ARR) of Confirmed Relapses — 0.205; 0.142; 0.150 Confirmed relapses per year

Primary: Objective Response Rate — 1; 15 Participants

Primary: Number, Frequency and Severity of Product Related Adverse Events — 47; 63; 110; 5 Number of product related Adverse Events

Primary: Change From Baseline to 6 Months in Gait Speed for 400 Meter Walking (MW) Test — 0.0093; 0.0457; 0.0478; -0.2886 Meter/Second (m/s) — p=0.2437

Primary: Participants' Perceived Fitness to Drive Measurement — 6.5; 4.6 units on a scale

Primary: Number of Participants With Suicidal Ideation — 4; 3; 0; 0 Participants — p=0.961

Primary: Number of Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388 — 7; 3; 6; 2 events

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity — 98; 89; 123; 91 Participants

Primary: Glucagon Response to Induced Hypoglycemia — 4.8; 8.8; 5.8; 4.2 pg/mL